Researchers have been battling to find the cure for cancer since we began to understand what cancer really was. A cure is the ultimate goal, but most medical professionals and patients would be ecstatic even hearing about new treatments. Current cancer treatments often come rife with side effects so severe that many choose to forgo them altogether. Stopping the growth of malicious cancer cells is the main goal of treatment, and removing them altogether is even better. The problem is, this kind of treatment almost always causes damage to surrounding healthy cells.
A treatment that changes cancerous cells into healthy, supportive cells sounds ideal. Transforming malignant cells into antibodies that would attack remaining cancer cells sounds too good to be true. Thanks to a groundbreaking study by scientists at The Scripps Research Institute (TSRI), this new, powerful form of cancer therapy could really be on the horizon.
An Accidental Discovery
The laboratory team was working on therapies for certain immune cell or blood factor deficiencies when they noticed some unusual effects of antibodies on marrow cells. They had been searching for antibodies that activate growth-factor receptors on immature bone marrow cells, meaning the antibodies would be able to induce these cells to mature into specific blood cell types.
After successfully identifying a number of antibodies that activated the bone marrow cell-receptors this way, the researchers noticed that some of the antibodies were having unexpected effects on the cells. Some of them were maturing into cells that were radically different from what had been expected, such as neural cells. This got the team thinking, could this method be used to convert cancerous marrow cells (leukemia cells) into non-cancerous cells?
In the new study, Richard A. Lerner, institute professor and the Lita Annenberg Hazen professor of Immunochemistry at TSRI and senior investigator, teamed up with colleagues, including first author Kyungmoo Yea, an assistant professor of cellular and molecular biology at TSRI. They decided to test 20 of the recently discovered receptor-activating antibodies on acute myeloid leukemia cells taken from human patients. One of the antibodies ended up having an incredible impact on the leukemia cells.
Most acute myeloid leukemia cells have the thrombopoietin (TPO) receptor, a receptor the winning antibody selectively and potently activated in marrow cells. When the antibody was applied to healthy marrow cells, the cells matured into blood-platelet-producing cells (megakaryocytes). When applied to the acute myeloid leukemia cells, though, the antibody caused them to mature into dendritic cells, which are key support cells in the body’s immune system.
This alone would have been a success — the researchers had effectively transformed cancerous cells into non-cancerous, helpful immune system cells. The team pushed further, though, and found that with longer exposures to the antibodies and other regulated conditions, the dendritic cells matured even more. The final product was a group of cells that very closely resembled natural killer (NK) cells. One of the body’s rapid immune defenses, NK cells are capable of rapidly attacking potentially dangerous pathogens and tumors even if they don’t contain the biomarkers normally identified by other immune cells.
“That antibody could have turned those acute myeloid leukemia cells into a lot of other cell types, but somehow we were lucky enough to get NK cells,” Lerner said in a press release.
These induced NK cells possessed a few unique characteristics, observed by the team through electron microscopy. The cells possessed extending tendrils that had made their way through the outer membranes of closeby leukemia cells — the kind of cells they would still be, had they not been exposed to the antibody. In lab tests, the NK cells betrayed their former brethren at an impressive pace: a “modest” number of NK cells took out about 15 percent of the surrounding leukemic cell population in only 24 hours.
An interesting detail noted by the researchers is the purely fratricidal nature of the NK cells. They attacked only related leukemia cells, while unrelated breast cancer cells did not die off in large numbers when put into contact with the NK cells. The team is still unclear on why exactly the NK cells behave this way, but hypothesize that other, yet-to-be-discovered antibodies could be the key to turning other cancerous cell types into NK cells.
Lerner has named this type of therapy “fratricidins,” and pointed out that they would have several advantages. The antibodies would be clinically useful with little to no modification, and the high specificity of the NK cells would reduce the likelihood of damage to surrounding healthy cells. This would make fratricidins a possible treatment with much more tolerable effects than traditional treatments like chemotherapy.
On top of that, every cancer cell in a population is potentially convertible, so in a successful therapy the cancer-cell population might not just be reduced, but eliminated entirely.
The Latest on: Cancer Treatment Breakthrough
via Google News
The Latest on: Cancer Treatment Breakthrough
- Pembrolizumab plus Chemo Granted Breakthrough Therapy Designation by the FDAon October 20, 2019 at 5:51 pm
Barts Cancer Institute. “There is significant need for new treatment regimens that can increase pCR rates in this patient population.” Pembrolizumab (KEYTRUDA) plus chemotherapy was granted ...
- Immunotherapy a 'breakthrough' in breast cancer treatmenton October 19, 2019 at 10:09 pm
Though it's unclear if immunotherapy is the lone factor in Witten's progress, Agrawal said that innovations like it have helped to push the field of cancer treatment forward, adding that it's an ...
- Malaysian Scientist Wins the ‘Nobel Prize for Cancer Research’ With Breakthrough in Treatmenton October 18, 2019 at 3:16 pm
Originally also known as the “Nobel Prize for Cancer Research,” the award was given to Dr. Nik-Zainal along with her collaborators Dr. Paul Calleja and Dr. Ignacio Medina from the University ...
- Effective Second-Line Treatment for Mesothelioma Gaining Groundon October 17, 2019 at 8:40 am
“It could prove eventually to be a real breakthrough. This was a good first step ... Lurbinectedin also has shown effectiveness recently in a second-line setting for the treatment of small-cell lung ...
- Cleveland Diagnostics Announces FDA Breakthrough Device Designation for Novel Prostate Cancer Diagnostic Teston October 16, 2019 at 6:01 am
tests in detecting high-grade prostate cancer. FDA Breakthrough Device designation is granted to novel medical devices that have the potential to provide more effective treatment or diagnosis of ...
- This scientist spent years working on a breakthrough cancer drug. Now he's got it.on October 15, 2019 at 12:15 pm
It's been a constant in his life since then. Ultimately Polivy — the prefix of the branded drug and its scientific name, polatuzumab vedotin, honors Polson — won its FDA approval as a treatment for ...
- Liver cancer pipeline: 6 latest reportson October 14, 2019 at 6:05 am
FDA grants breakthrough designation to liver cancer liquid biopsy test The Laboratory ... cancer Eureka Therapeutics has initiated a phase 1/2 clinical trial of its ET140202 Artemis T-cell therapy for ...
- Breakthrough study by Kaiser Permanente supports outpatient breast cancer surgeryon October 12, 2019 at 8:07 pm
Mindemann sees a patient right after the woman gets a test result indicating cancer. She lays out the entire medical journey, including treatment options and potential doctors involved. “I present it ...
- FDA Approval in Myeloma, Label Update in HER2+ Breast Cancer, Breakthrough Status in Prostate Cancer, and Moreon October 11, 2019 at 6:06 pm
The FDA initially approved neratinib in July 2017 for the extended adjuvant treatment of adult patients with early-stage, HER2-positive breast cancer following adjuvant trastuzumab-based therapy. The ...
- Breakthrough in cancer research discovered in South Bendon October 11, 2019 at 5:38 am
SOUTH BEND, Ind. --- Researchers at the University of Notre Dame made a breakthrough discovery in cancer research. The discovery is believed to be an explanation as to how breast cancer can spread to ...
via Bing News